Cited by 878Influenza Virus Research StudiesRespiratory viral infections researchBacterial Infections and Vaccines

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

Open access

DiazGranados, Carlos A., Dunning, Andrew J., Kimmel, Murray, Kirby, Daniel, Treanor, John, Collins, Avi, Pollak, Richard, Christoff, Janet, Earl, John, Landolfi, Victoria, Martin, Earl, Gurunathan, Sanjay, Nathan, Richard, Greenberg, David P., Tornieporth, Nadia G., Decker, Michael D., Talbot, H. Keipp·2014·New England Journal of Medicine

DOI 10.1056/nejmoa1315727

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 years of age or older. This study evaluated whether IIV3-HD also improves protection against laboratory-confirmed influenza illness. METHODS: We conducted a phase IIIb-IV, multicenter, randomized, double-blind, active-controlled trial to compare IIV3-HD (60 μg of hemagglutinin per strain) with standard-dose trivalent, inactivated influenza vaccine (IIV3-SD [15 μg of hemagglutinin per strain]) in adults 65 years of age or older. Assessments of relative efficacy, effectiveness, safety (serious adverse events), and immunogenicity (hemagglutination-inhibition [HAI] titers) were performed during the 2011-2012 (year 1) and the 2012-2013 (year 2) northern-hemisphere influenza seasons. RESULTS: A total of 31,989 participants were enrolled from 126 research centers in the United States and Canada (15,991 were randomly assigned to receive IIV3-HD, and 15,998 to receive IIV3-SD). In the intention-to-treat analysis, 228 participants in the IIV3-HD group (1.4%) and 301 participants in the IIV3-SD group (1.9%) had laboratory-confirmed influenza caused by any viral type or subtype associated with a protocol-defined influenza-like illness (relative efficacy, 24.2%; 95% confidence interval [CI], 9.7 to 36.5). At least one serious adverse event during the safety surveillance period was reported by 1323 (8.3%) of the participants in the IIV3-HD group, as compared with 1442 (9.0%) of the participants in the IIV3-SD group (relative risk, 0.92; 95% CI, 0.85 to 0.99). After vaccination, HAI titers and seroprotection rates (the percentage of participants with HAI titers ≥ 1:40) were significantly higher in the IIV3-HD group. Conclusions: Among persons 65 years of age or older, IIV3-HD induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than did IIV3-SD. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01427309.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1315727

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Fiore, A. E., Shay, D. K., Broder, K. R., Iskander, J. K., Uyeki, T. M., Mootrey, G., Bresee, J. S., & Cox, N. S. (2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,006
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
Fiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 1,964
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100
The Efficacy of Influenza Vaccination in Elderly Individuals
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 883
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
Simonsen, L., Reichert, T. A., Viboud, C. G., Blackwelder, W. C., Taylor, R. J., & Miller, M. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 541
Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J. (2009) · The Journal of Infectious Diseases · doi:10.1086/599790 · Cited by 388
Self-citation
Influenza Activity — United States, 2015–16 Season and Composition of the 2016–17 Influenza Vaccine
Davlin, S. L., Blanton, L., Kniss, K. L., Mustaquim, D., Smith, S., Kramer, N. A., Cohen, J., Cummings, C. N., Garg, S., Flannery, B. L., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6522a3 · Cited by 328

Show all 29 references

Research works printed but not linked: 7

Fiore AE, 2010, MMWR Recomm Rep, 59, 1
Praditsuwan R, 2005, J Med Assoc Thai, 88, 256
10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I · DOI · Paper page
2012, MMWR Morb Mortal Wkly Rep, 61, 414
2013, MMWR Morb Mortal Wkly Rep, 62, 997
2013, MMWR Morb Mortal Wkly Rep, 62, 473
2013, Wkly Epidemiol Rec, 88, 101

Sorted by citations

Items 401–500 of 878

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old
Keitel, W. A., Jackson, L. A., Edupuganti, S., Winokur, P. L., Mulligan, M. J., Thornburg, N. J., Patel, S. M., Rouphael, N., Lai, L., Bangaru, S., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv056 · Cited by 13
Multi‐site placebo‐controlled randomised clinical trial to assess protection following oral immunisation with inactivated non‐typeable Haemophilus influenzae in chronic obstructive pulmonary disease
Clancy, R. L., Dunkley, M. L., Sockler, J., & McDonald, C. F. (2016) · Internal Medicine Journal · doi:10.1111/imj.13072 · Cited by 13
Influenza: overview on prevention and therapy
Robson, C., Baskar, S. R., Booy, R., Ferguson, P. E., Gilroy, N. M., Kok, J., Sandaradura, I., & Dwyer, D. E. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.013 · Cited by 13
Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial
L’Huillier, A. G., Ferreira, V. H., Hirzel, C., Natori, Y., Slomovic, J., Ku, T., Höschler, K., Ierullo, M., Selzner, N., Schiff, J. R., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz471 · Cited by 13
Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice
Dhakal, S., Deshpande, S., McMahon, M., Strohmeier, S., Krammer, F., & Klein, S. L. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.11.057 · Cited by 13
Guillain-Barré Syndrome Following Influenza Vaccines Affords Opportunity to Improve Vaccine Confidence
Salmon, D. A., Dudley, M. Z., & Carleton, B. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa544 · Cited by 13
Immunosenescence and susceptibility to respiratory viruses: a state-of-the-art review
Fragkou, P. C., Skevaki, C. L., Moschopoulos, C. D., Keske, Ş., Wozniak, H., Malézieux-Picard, A., Prendki, V., & Rello, J. (2026) · European Respiratory Review · doi:10.1183/16000617.0248-2025 · Cited by 12
Vaccination in Chronic Obstructive Pulmonary Disease
Kwok, W. C., Wong, J.-N. C., Cheung, A., & Tam, T. C. C. (2025) · Vaccines · doi:10.3390/vaccines13030218 · Cited by 12
Influenza vaccination in the elderly: Is a trial on mortality ethically acceptable?
Verhees, R. A. F., Dondorp, W., Thijs, C. T., Dinant, G., & Knottnerus, J. A. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.04.027 · Cited by 12
High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010–2013
McGrath, L. J., Layton, J. B., Krueger, W. S., Kshirsagar, A. V., & Butler, A. M. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.079 · Cited by 12
Study of the Immune Response in the Elderly: Is It Necessary to Develop a Vaccine againstNeisseria meningitidisfor the Aged?
de Lima, G. T., & Gaspari, E. D. (2019) · Journal of Aging Research · doi:10.1155/2019/9287121 · Cited by 12
Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States
Net, P., Colrat, F., Costa, M. N., Bianic, F., Thommes, E. W., & Alvarez, F. P. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.016 · Cited by 12
Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales
Mattock, R., Gibbons, I., Moss, J. W. E., Mealing, S., Largeron, N., Carroll, S., & Alvarez, F. P. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.2000780 · Cited by 12
Expert opinion on strategies to improve vaccination coverage against seasonal influenza
Peñas, C. V., Pérez, V. M. D. C., Calle, I. R., del Olmo, L. A., Pérez-Rodríguez, M. T., & Otero, J. J. G. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/031.2022 · Cited by 12
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
Raptis, C., Berger, C. T., Ciurea, A., Andrey, D. O., Polysopoulos, C., Lescuyer, P., Maletic, T., Riek, M., Scherer, A., von Loga, I., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016927 · Cited by 12
Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population
Marbaix, S., Dauby, N., & Mould-Quevedo, J. F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2229917 · Cited by 12
Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status
Zhong, S., Ng, T. W. Y., Skowronski, D. M., Iuliano, A. D., Leung, N., Perera, R. A. P. M., Ho, F. C. S., Fang, V. J., Tam, Y. H., Ip, D., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad497 · Cited by 12
Healthy elderly Singaporeans show no age-related humoral hyporesponsiveness nor diminished plasmablast generation in response to influenza vaccine
Camous, X., Visan, L., Ying, C., Abel, B., Nyunt, M. S. Z., Narang, V., Poidinger, M., Carré, C., Sesay, S., Bosco, N., et al. (2018) · Immunity & Ageing · doi:10.1186/s12979-018-0137-4 · Cited by 12
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
Moodie, Z., Walsh, S. R., Laher, F., Maganga, L., Herce, M. E., Naidoo, S., Hosseinipour, M. C., Innes, C., Bekker, L., Grunenberg, N. A., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003117 · Cited by 12
Vaccinations for the Older Adult
Gnanasekaran, G., Biedenbender, R., Davidson, H. E., & Gravenstein, S. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.03.001 · Cited by 12
Effective Immunization of Older Adults Against Seasonal Influenza
Schaffner, W., Chen, W. H., HOPKINS, R. H., & Neuzil, K. M. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.02.019 · Cited by 13
Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review
Bassendine, M. F., & Bridge, S. H. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2019.19152 · Cited by 12
Effectiveness of influenza vaccine in reducing influenza-associated hospitalizations and deaths among the elderly population; Lazio region, Italy, season 2016-2017
Fabiani, M., Volpe, E., Faraone, M., Bella, A., Pezzotti, P., & Chini, F. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1750380 · Cited by 12
High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/15
Young‐Xu, Y., Snider, J. T., Mahmud, S. M., Russo, E. M., van Aalst, R., Thommes, E. W., Lee, J. K. H., & Chit, A. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.19.1900401 · Cited by 12
Comparing the impact of high-dose versus standard dose influenza vaccines on hospitalization cost for cardiovascular and respiratory diseases: Economic assessment in the US Veteran population during 5 respiratory seasons using an instrumental variable method
van Aalst, R., Russo, E. M., Neupane, N., Mahmud, S. M., Wilschut, J., Samson, S., Chit, A., Postma, M. J., & Young‐Xu, Y. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.080 · Cited by 12
Is seasonal vaccination a contributing factor to the selection of influenza epidemic variants?
Chong, Y., & Ikematsu, H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1373228 · Cited by 12
Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization
Ingrole, R. S. J., Shakya, A. K., Joshi, G. V., Lee, C. H., Nesovic, L. D., Compans, R. W., & Gill, H. S. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01451-3 · Cited by 11
Assessing the prior event rate ratio method via probabilistic bias analysis on a Bayesian network
Thommes, E. W., Mahmud, S. M., Young‐Xu, Y., Snider, J. T., van Aalst, R., Lee, J. K. H., Halchenko, Y., Russo, E. M., & Chit, A. (2019) · Statistics in Medicine · doi:10.1002/sim.8435 · Cited by 11
The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and England
Nealon, J., Modin, D., Ghosh, R. E., Rudin, D., Gislason, G., Booth, H., Jensen, J. S., Williams, R., Shepherd, H., Yelland, E., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00444-6 · Cited by 11
Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data
Zheng, C., Duffy, J., Liu, I. A., Sy, L. S., Chen, W., Qian, L., Navarro, R. A., Ryan, D. S., Kim, S. S., Mercado, C., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-3023 · Cited by 11
Lessons learnt from influenza vaccination in immunocompromised children undergoing treatment for cancer
Furlong, E., & Kotecha, R. S. (2023) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00315-7 · Cited by 11
COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series
Walmsley, S. L., Szadkowski, L., Wouters, B. G., Clarke, R., Colwill, K., Rochon, P. A., Brudno, M., Ravindran, R., Raboud, J., McGeer, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106506 · Cited by 12
Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records
Atanasov, V. A., Barreto, N., Whittle, J., Meurer, J., Weston, B. W., Luo, Q., Yuan, A. Y., Franchi, L., Zhang, R., & Black, B. S. (2023) · Vaccines · doi:10.3390/vaccines11050971 · Cited by 11
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study
Qin, K., Honjo, K., Sherrill-Mix, S. A., Liu, W., Stoltz, R., Oman, A. K., Hall, L., Li, R., Sterrett, S., Frederick, E. R., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004157 · Cited by 11
Immunosenescence and Inflamm-Aging: Clinical Interventions and the Potential for Reversal of Aging
Kumar, S. J., Shukla, S., Kumar, S., & Mishra, P. (2024) · Cureus · doi:10.7759/cureus.53297 · Cited by 12
Diagnostic and therapeutic challenges of chronic obstructive pulmonary disease in the elderly
Allen, B., & Aboussouan, L. S. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000750 · Cited by 11
Achieving Influenza Vaccine Uptake Target in Canada via a Pharmacy-Led Telephone Discussion during the 2019–2020 Season
Strain, W. D., Mansi, J. A., Boikos, C., Boivin, M., & Fisher, W. A. (2021) · Vaccines · doi:10.3390/vaccines9040312 · Cited by 11
Key Determinants of Cell-Mediated Immune Responses: A Randomized Trial of High Dose Vs. Standard Dose Split-Virus Influenza Vaccine in Older Adults
Verschoor, C. P., Haynes, L., Pawelec, G., Loeb, M. B., Andrew, M. K., Kuchel, G. A., & McElhaney, J. E. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.649110 · Cited by 11
Significant publications on infectious diseases pharmacotherapy in 2014
Phe, K., Cadle, R. M., Guervil, D. J., Guzmán, O. E., Lockwood, A. M., Perez, K. K., Vuong, N. N., & Aitken, S. L. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150112 · Cited by 11
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis
Ruiz-Palacios, G. M., Leroux-Roels, G. G., Beran, J., Devaster, J., Esen, M., Launay, O., McElhaney, J. E., van Essen, G. A., Benoit, A. G., Claeys, C., et al. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1219809 · Cited by 11
Gaps in Aging Research as it Applies to Rheumatologic Clinical Care
Makris, U. E., Misra, D., & Yung, R. L. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.009 · Cited by 11
Vaccines in the Prevention of Viral Pneumonia
Fraser, C. S., Jha, A., & Openshaw, P. (2016) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2016.11.009 · Cited by 12
Effects of high‐dose versus standard‐dose quadrivalent influenza vaccine among patients with diabetes: A post‐hoc analysis of the DANFLU ‐1 trial
Lassen, M. C. H., Johansen, N. D., Modin, D., Nealon, J., Samson, S., Dufournet, M., Loiacono, M. M., Larsen, C. S., Jensen, A. M. R., Landler, N. E., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15498 · Cited by 10
Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: A post hoc analysis of the DANFLU-1 randomized clinical trial
Christensen, J., Johansen, N. D., Janstrup, K. H., Modin, D., Skaarup, K. G., Nealon, J., Samson, S., Loiacono, M. M., Harris, R. C., Larsen, C. S., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106276 · Cited by 11
Respiratory Viral Infections in Transplant Recipients
Liu, C., Ho, D. Y., & Boeckh, M. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_40 · Cited by 10
Vaccination efficacy in patients with chronic lymphocytic leukemia
Wang, K. Y., Shah, P., Skavla, B., Fayyaz, F., Chi, J., & Rhodes, J. M. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2133538 · Cited by 10
Repeated influenza vaccination induces similar immune protection as first‐time vaccination but with differing immune responses
Ye, B., Shu, L., Pang, Y., Guo, Y., Guo, Y., Zong, K., Chen, C., Zheng, X., Zhang, J., Liu, M., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13060 · Cited by 10
T Cell Transcriptional Signatures of Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine in Older Adults
Haralambieva, I. H., Quach, H. Q., Ovsyannikova, I. G., Goergen, K. M., Grill, D. E., Poland, G. A., & Kennedy, R. B. (2022) · Viruses · doi:10.3390/v14122763 · Cited by 10
Vaccine-Preventable Diseases in Older Adults
Al-Jabri, M., Rosero, C., & Saade, E. (2023) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.09.009 · Cited by 10
Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020
Naleway, A. L., Kim, S. S., Flannery, B. L., Levine, M. Z., Murthy, K., Sambhara, S. R., Gangappa, S., Edwards, L., Ball, S. W., Grant, L., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad223 · Cited by 10
Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe
Chicoye, A., Crépey, P., Nguyen, V. H., Márquez-Peláez, S., Postma, M. J., Pugliese, A., Ruiz-Aragón, J., & Mould-Quevedo, J. F. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.073 · Cited by 10
Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
Jaishwal, P., Jha, K., & Singh, S. P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134012 · Cited by 10
Influenza vaccination among children with idiopathic nephrotic syndrome: an investigation of practices
Klifa, R., Toubiana, J., Michel, A., Biebuyck, N., Charbit, M., Heidet, L., Krid, S., Krug, P., Salomon, R., & Boyer, O. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1240-2 · Cited by 10
Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults
Vanderven, H. A., Barr, I., Reynaldi, A., Wheatley, A. K., Wines, B. D., Davenport, M. P., Hogarth, P. M., & Kent, S. J. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.01.066 · Cited by 10
Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50–64 Years, and At-Risk Adults Aged 19–64 Years
Choi, M. J., Shin, G., Kang, D., Lim, J.-O., Kim, Y. K., Choi, W. S., Yun, J.-W., Noh, J. Y., Song, J. Y., Kim, W. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10030445 · Cited by 10
A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models
Feng, J., Du, Y., Chen, L., Su, W., Wei, H., Liu, A., Jiang, X., Guo, J., Dai, C., Xu, Y., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.056 · Cited by 9
Boosting effect of high-dose influenza vaccination on innate immunity among elderly
Bonduelle, O., Delory, T., Moscardini, I. F., Ghidi, M., Bennacer, S., Wokam, M., Lenormand, M., Petrier, M., Rogeaux, O., de Bernard, S., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.184128 · Cited by 9
An Oral Whole-Cell Killed Nontypeable Haemophilus influenzae Immunotherapeutic For The Prevention Of Acute Exacerbations Of Chronic Airway Disease
Clancy, R. L., & Cripps, A. W. (2019) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s217317 · Cited by 8
Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial
Sanchez, L., Nakama, T., Nagai, H., Matsuoka, O., Inoue, S., Inoue, T., Shrestha, A., Pandey, A., Chang, L.-J., & Bruijn, I. D. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.071 · Cited by 9
Healthcare maintenance in elderly patients with inflammatory bowel disease
Shrestha, M. P. (2016) · Annals of Gastroenterology · doi:10.20524/aog.2017.0130 · Cited by 9
Preventing the Risk of Hospitalization for Respiratory Complications of Influenza among the Elderly: Is There a Better Influenza Vaccination Strategy? A Retrospective Population Study
Cocchio, S., Gallo, T., Zotto, S. D., Clagnan, E., Iob, A., Furlan, P., Fonzo, M., Bertoncello, C., & Baldo, V. (2020) · Vaccines · doi:10.3390/vaccines8030344 · Cited by 9
Moving Toward Improved Influenza Vaccines
Monto, A. S. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw644 · Cited by 9
Racial disparities in influenza vaccination
Sundaram, M. E., & Pamplin, J. R. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00027-1 · Cited by 9
A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older
Essink, B. J., Vermeulen, W., Andrade, C., de Rooij, R., Isakov, L., Casula, D., & Albano, F. R. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126791 · Cited by 8
The Evolution of Annual Immunization Recommendations Against Influenza in Italy: The Path to Precision Vaccination
Boccalini, S., de Waure, C., Martorella, L., Orlando, P., Bonanni, P., & Bechini, A. (2025) · Vaccines · doi:10.3390/vaccines13040356 · Cited by 8
Leveraging pre-vaccination antibody titres across multiple influenza H3N2 variants to forecast the post-vaccination response
Stacey, H. D., Carlock, M. A., Allen, J. D., Hanley, H. B., Crotty, S., Ross, T. M., & Einav, T. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105744 · Cited by 8
Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza season
Imran, M., Chastek, B. J., Bancroft, T., Webb, N. S., Pelton, S. I., Haag, M. D. M., & McGovern, I. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.107983 · Cited by 8
High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial
Pareek, M., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager‐Pedersen, M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf678 · Cited by 8
Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults
Hsiao, A., Leong, T. K., FIREMAN, B. H., Hansen, J., Zerbo, O., Jacobson, K. B., Liao, L. D., Haag, M. D. M., McGovern, I., Zhang, B., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.10120 · Cited by 8
Vaccination of Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic.
Crosby, S. K., Schuh, M. J., Caldera, F., & Farraye, F. A. (2021) · PubMed Central · Cited by 8
Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study
Chen, J., Hsieh, S., Hwang, S., Liu, C.-S., Li, X., Fournier, M., Yeh, T., Yin, J. K., & Samson, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.078 · Cited by 8
Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination
Boudreau, C. M., Burke, J. S., Roederer, A. L., Gorman, M. J., Mundle, S. T., Lingwood, D., Delagrave, S., Sridhar, S., Ross, T. M., Kleanthous, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100975 · Cited by 8
Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial
Widagdo, W., Bastian, A. R., Jastorff, A. M., Scheys, I., Paepe, E. D., Comeaux, C. A., Ligtenberg, N., Callendret, B., & Heijnen, E. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad594 · Cited by 8
Influenza Viruses
Treanor, J. J. (2023) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_19-2 · Cited by 8
Self-citation
Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults
Beck, E. C., Georgieva, M. V., Wang, W., Gómez-Liévano, A., Wang, H., Gao, Y., Kopel, H., Bausch-Jurken, M. T., Patterson‐Lomba, O., Mu, F., et al. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2466726 · Cited by 9
Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025
Blanquart, F., Vieillefond, V., Visseaux, B., Chakra, C. N. A., Nunes, M. C., Jacques, A., Haïm‐Boukobza, S., Josset, L., Wehrle, V., Deleglise, G., et al. (2025) · Eurosurveillance · doi:10.2807/1560-7917.es.2025.30.7.2500074 · Cited by 8
Recent developments of vaccines for older adults: Adjuvants and beyond
Pangrazzi, L., & Weinberger, B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2517931 · Cited by 9
Biometric Strategies to Improve Vaccine Immunogenicity and Effectiveness
Clemente‐Suárez, V. J., Redondo-Flórez, L., Bustamante-Sánchez, Á., Martín-Rodríguez, A., Sepulveda, R. A. Y., & Tornero-Aguilera, J. F. (2025) · Biomimetics · doi:10.3390/biomimetics10070439 · Cited by 8
Influenza Vaccine Failure Associated With Age and Immunosuppression
Kimball, J., Zhu, Y., Wyatt, D., Trabue, C. H., & Talbot, H. K. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa757 · Cited by 8
Self-citation
Impact of General Practitioner Education on Acceptance of an Adjuvanted Seasonal Influenza Vaccine among Older Adults in England
de Lusignan, S., Ashraf, M., Ferreira, F. M., Tripathy, M., Yonova, I., Rafi, I., Kassianos, G. C., & Joy, M. (2023) · Behavioral Sciences · doi:10.3390/bs13020130 · Cited by 8
The intranasal adjuvant Endocine™ enhances both systemic and mucosal immune responses in aged mice immunized with influenza antigen
Falkeborn, T., Hinkula, J., Olliver, M., Lindberg, A. A., & Maltais, A.-K. (2017) · Virology Journal · doi:10.1186/s12985-017-0698-4 · Cited by 8
Surveillance of medically‐attended influenza in elderly patients from Romania—data from three consecutive influenza seasons (2015/16, 2016/17, and 2017/18)
Pițigoi, D., Streinu‐Cercel, A., Ivanciuc, A. E., Lazăr, M., Cherciu, C. M., Mihai, M. E., Nițescu, M., Aramă, V., Crăciun, M., Streinu‐Cercel, A., et al. (2020) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12752 · Cited by 8
Relative Vaccine Efficacy of High-Dose Versus Standard-Dose Influenza Vaccines in Preventing Probable Influenza in a Medicare Fee-for-Service Population
Paudel, M. L., Mahmud, S. M., Buikema, A. R., Korrer, S., Voorhis, D. V., Brekke, L. N., & Chit, A. (2019) · Vaccine · doi:10.1016/j.vaccine.2020.05.020 · Cited by 8
High-dose trivalent influenza vaccine: safety and immunogenicity
de Lejarazu, R. O., Martinón‐Torres, F., de Miguel, Á. G., Díez‐Domingo, J., & Margüello, E. R. (2020) · Revista Española de Quimioterapia · doi:10.37201/req/110.2020 · Cited by 8
Repeat Influenza Vaccination and High-Dose Efficacy
Skowronski, D. M., Chambers, C., Gilca, R., & Serres, G. D. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw544 · Cited by 8
Influenza vaccination in older people: a geriatrician’s perspective
Veronese, N., Dominguez, L. J., Ganci, A., Speziale, G., Mansueto, P., Piro, S., Basile, G., & Barbagallo, M. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03086-5 · Cited by 7
High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial
Skaarup, K. G., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager‐Pedersen, M., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013678 · Cited by 7
Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial
Daulagala, P., Leung, Y. W. Y., Luk, L. L. H., Ho, F. C. S., Chu, S. H. N., Lin, J., Cheng, S. M. S., Leung, N., Eichelberger, M. C., Peiris, M. J. S., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf616 · Cited by 7
Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
Lu, L., Fong, C. H.-Y., Zhang, J., Wu, W., Li, I. C., Lee, A. C.-Y., Dissanayake, T. K., Chen, L., Hung, I. F., Chan, K., et al. (2020) · Vaccines · doi:10.3390/vaccines8040754 · Cited by 7
Analysis of R848 as an Adjuvant to Improve Inactivated Influenza Vaccine Immunogenicity in Elderly Nonhuman Primates
Crofts, K. F., Holbrook, B. C., D’Agostino, R. B., & Alexander‐Miller, M. A. (2022) · Vaccines · doi:10.3390/vaccines10040494 · Cited by 8
Local Response and Barrier Recovery in Elderly Skin Following the Application of High-Density Microarray Patches
Iredahl, F., Muller, D. A., Togö, T., Jonasson, H., Baker, B., Anderson, C. D., & Henricson, J. (2022) · Vaccines · doi:10.3390/vaccines10040583 · Cited by 7
Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
Nham, E., Seong, H., Hyun, H., Yoon, J. G., Noh, J. Y., Cheong, H. J., Kim, W. J., Kim, E., Choi, L., Lee, J.-M., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2266233 · Cited by 7
Vaccination choices for older people, looking beyond age specific approaches
Aspinall, R., & Lang, P. O. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1411197 · Cited by 7
Special Considerations for Vaccines and the Elderly
Saade, E., Canaday, D. H., Davidson, H. E., Han, L., & Gravenstein, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00003-3 · Cited by 8
Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population
Rumi, F., Basile, M., & Cicchetti, A. (2021) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2021.2247 · Cited by 7
An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
Ruiz-Aragón, J., & Márquez-Peláez, S. (2023) · Vaccines · doi:10.3390/vaccines11020427 · Cited by 7
Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
Rumi, F., Basile, M., Cicchetti, A., Alvarez, F. P., Azzi, M. V., & Muzii, B. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1200116 · Cited by 7
Influenza Vaccines and Vaccination Strategies
Neuzil, K. M., & Ortiz, J. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00021-7 · Cited by 7
The global challenge and future strategies for keeping the world's aging population healthy by vaccination
Steeper, M., Plebanski, M., & Flanagan, K. L. (2016) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trw054 · Cited by 7
Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis
Smith, K. J., France, G., Nowalk, M. P., Raviotta, J. M., DePasse, J. V., Wateska, A. R., Shim, E., & Zimmerman, R. K. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2018.11.015 · Cited by 7

Authors: DiazGranados, C. A., Dunning, A. J., Kimmel, M., Kirby, D., Treanor, J., Collins, A., Pollak, R., Christoff, J., Earl, J., Landolfi, V., Martin, E., Gurunathan, S., Nathan, R., Greenberg, D. P., Tornieporth, N. G., Decker, M. D., & Talbot, H. K.
Affiliations: University of Pittsburgh (US)
University of Rochester (US)
PMG Research (US)
Martin Diagnostic Clinic (US)
Vanderbilt University (US)
Vanderbilt University Medical Center (US)
ORCID: Dunning, Andrew J.
Gurunathan, Sanjay
Decker, Michael D.
Talbot, H. Keipp
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2014-08-14
Volume: 371
Issue: 7
Pages: 635-645
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1315727
OpenAlex: W2168805652
Cited by: 876
References: 29
Citations by year: 2026: 76 · 2025: 89 · 2024: 60 · 2023: 78 · 2022: 68 · 2021: 95 · 2020: 80 · 2019: 78 · 2018: 68 · 2017: 65 · 2016: 65 · 2015: 42 · 2014: 10
FWCI: 45.92
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords: high-dose influenza vaccine, trivalent inactivated influenza vaccine, older adults, vaccine efficacy, laboratory-confirmed influenza, hemagglutination inhibition titers, immunogenicity, seroprotection, serious adverse events, influenza vaccination, 2011-2012 influenza season, 2012-2013 influenza season, antibody response
MeSH terms: Aged, Antibodies, Viral, Chronic Disease, Double-Blind Method, Female, Humans, Influenza, Human, Influenza Vaccines, Male, Orthomyxoviridae, Vaccines, Inactivated, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks